Amarin Corporation Plc (AMRN) 0.95 $AMRN
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
at The Street - Fri Nov 14, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OREX: 5.65 (-0.21), AMRN: 0.95 (unch), ICPT: 162.58 (+3.72), SPPI: 7.21 (-0.04), MNKD: 6.16 (-0.02)
Rick Harrison of Television's "Pawn Stars(R)" Takes His Patient-Care Message to AHA Scientific Sessions to Raise Awareness of Very High Triglycerides as Part of National Campaign
Marketwired - Thu Nov 13, 6:04AM CST
Making the right deal can meaningfully impact and improve your health when it comes to speaking with your doctor. Rick Harrison, star of the hit television show, "Pawn Stars®," will attend the American Heart Association's (AHA) Scientific Sessions to raise awareness of very high triglycerides (VHTG) (≥ 500 mg/dL), a condition that affects up to four million Americans.(1) Mr. Harrison's AHA visit is sponsored by Amarin Corporation, plc (NASDAQ: AMRN).
AMRN: 0.95 (unch)
Update: Amarin's Q3 2014 Earnings Report
Elephant Analytics - at Seeking Alpha - Mon Nov 10, 12:18AM CST
AMRN: 0.95 (unch)
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations
Marketwired - Thu Nov 06, 3:04PM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on company operations.
AMRN: 0.95 (unch)
Amarin misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:03PM CST
AMRN: 0.95 (unch)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.60 (+0.21), ACET: 21.10 (-0.19), ANET: 77.69 (+0.72), FNGN: 32.91 (+0.55), CPST: 0.92 (-0.02), AUQ: 3.78 (+0.27), AMRN: 0.95 (unch), ED: 62.03 (+0.03), ENV: 54.50 (+0.39), FXCM: 16.66 (+0.06), BCEI: 39.11 (+1.00), GXP: 26.38 (-0.05), EAC: 11.96 (-0.47), DXCM: 52.73 (-0.90), CSC: 61.76 (+0.09), AEL: 27.20 (+0.09), HNSN: 0.84 (+0.04), CFN: 57.57 (+0.01), ANAC: 31.00 (-0.46), DAR: 18.81 (+0.11), GST: 4.12 (+0.25), ARC: 9.59 (-0.29), FIVN: 4.97 (+0.03), ELON: 1.91 (-0.01), FSLR: 48.49 (+0.93), EZPW: 10.97 (-0.21), ALIM: 5.24 (+0.07), FWM: 2.30 (unch), BRS: 70.80 (-0.34), ECOM: 18.85 (-0.05), FTEK: 3.85 (-0.05), CVT: 28.15 (-0.10), AL: 36.97 (+0.03), BBRG: 13.15 (-0.02), BPZ: 1.00 (+0.06), ECPG: 44.62 (-0.61), HTGC: 15.56 (+0.04), AIRM: 44.22 (+0.23), BNFT: 26.65 (+0.61), ENOC: 15.21 (+0.42), HPTX: 21.19 (-0.40), AGO: 24.94 (+0.08), FICO: 71.44 (-0.37), FF: 12.42 (+0.24), FI: 20.63 (+0.61), EVC: 5.46 (+0.22), EBS: 24.22 (-0.10), ABCO: 46.38 (+0.16), DIOD: 26.34 (+0.57), DIS: 90.80 (+0.31), EGOV: 17.77 (+0.48), APEI: 36.62 (+0.77), DVA: 75.66 (-1.38), CLVS: 54.89 (-1.91), HCI: 43.04 (+1.24), BRKR: 18.11 (-0.19), HGR: 21.20 (-0.04)
Amarin to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November 6, 2014
ACCESSWIRE - Wed Nov 05, 3:56PM CST
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / November 5, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, November 6, 2014 at 4:30 PM Eastern Time.
AMRN: 0.95 (unch)
Amarin reports November 6
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:37PM CST
AMRN: 0.95 (unch)
Amarin to Report Third Quarter 2014 Results and Host Conference Call on November 6, 2014
Marketwired - Thu Oct 30, 6:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2014 financial results and provide an operational update on Thursday, November 6, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's third quarter 2014 financial results earlier that day.
AMRN: 0.95 (unch)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 14.68 (-0.92), BIIB: 305.43 (-12.55), AMRN: 0.95 (unch), UTHR: 125.43 (unch), NLNK: 30.54 (-0.46)
Amarin's Value With Or Without REDUCE-IT And A Final Word On Management
Outsized Analytics - Seeking Alpha - Wed Oct 22, 11:30PM CDT
For Amarin (NASDAQ: AMRN ) investors, the 4th quarter of 2014 may feel more like the 4th quarter of a game nearing its end; patiently waiting for your team to mount a historic comeback while closely monitoring its cash flow and hoping the clock does...
AMRN: 0.95 (unch)
Update: Amarin Announces Its Q3 2014 Cash Balance
Elephant Analytics - at Seeking Alpha - Mon Oct 20, 4:27AM CDT
AMRN: 0.95 (unch)
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
PR Newswire - Mon Sep 22, 7:40AM CDT
The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 751.48, up 0.10%, with the index gaining 6.95% in the previous three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free research on these five companies can be accessed at:
SGYP: 3.00 (-0.07), ENZN: 1.09 (unch), AMRN: 0.95 (unch), ALKS: 51.47 (-1.75), ARRY: 3.55 (-0.13)
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
MDVN: 106.90 (-0.31), OREX: 5.65 (-0.21), AVNR: 13.13 (-0.01), GILD: 102.06 (-2.14), AMRN: 0.95 (unch), NPSP: 29.00 (-0.78), CELG: 104.05 (-3.38)
Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study
Marketwire - Tue Sep 16, 12:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study. This multinational, prospective, randomized, double-blind, placebo-controlled study is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels.
AMRN: 0.95 (unch)
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
BIIB: 305.43 (-12.55), GILD: 102.06 (-2.14), AMRN: 0.95 (unch), AMGN: 157.68 (-3.17)
Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Fri Sep 12, 10:39AM CDT
Shares of Amarin (AMRN) plummeted Friday after the FDA denied Amarin's appeal to reinstate Special Protocol Assessment status on a phase III study of the company's prescription fish-oil pill Vascepa.
AMRN: 0.95 (unch)
Investors look to Lighten Up on Shares of Amarin, Shares Down 20.4% (AMRN)
Comtex SmarTrend(R) - Fri Sep 12, 10:08AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 20.4% to $1.44 on 2.4x average daily volume. Amarin has traded 6.8 million shares thus far today, vs. average volume of 2.9 million shares per day. The stock has underperformed the Dow (-20.4% to the Dow's -0.1%) and underperformed the S&P 500 (-20.4% to the S&P's -0.2%) during today's trading.
AMRN: 0.95 (unch)
Why Amarin Corporation plc Stock Cratered
George Budwell, The Motley Fool - Motley Fool - Fri Sep 12, 9:28AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin Corporation are down over 20%...
AMRN: 0.95 (unch), GSK: 45.74 (+0.08)
Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
at The Street - Fri Sep 12, 8:43AM CDT
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
AMRN: 0.95 (unch)
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
at The Street - Fri Nov 14, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OREX: 5.65 (-0.21), AMRN: 0.95 (unch), ICPT: 162.58 (+3.72), SPPI: 7.21 (-0.04), MNKD: 6.16 (-0.02)
Rick Harrison of Television's "Pawn Stars(R)" Takes His Patient-Care Message to AHA Scientific Sessions to Raise Awareness of Very High Triglycerides as Part of National Campaign
Marketwired - Thu Nov 13, 6:04AM CST
Making the right deal can meaningfully impact and improve your health when it comes to speaking with your doctor. Rick Harrison, star of the hit television show, "Pawn Stars®," will attend the American Heart Association's (AHA) Scientific Sessions to raise awareness of very high triglycerides (VHTG) (≥ 500 mg/dL), a condition that affects up to four million Americans.(1) Mr. Harrison's AHA visit is sponsored by Amarin Corporation, plc (NASDAQ: AMRN).
AMRN: 0.95 (unch)
Update: Amarin's Q3 2014 Earnings Report
Elephant Analytics - at Seeking Alpha - Mon Nov 10, 12:18AM CST
AMRN: 0.95 (unch)
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations
Marketwired - Thu Nov 06, 3:04PM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on company operations.
AMRN: 0.95 (unch)
Amarin misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:03PM CST
AMRN: 0.95 (unch)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.60 (+0.21), ACET: 21.10 (-0.19), ANET: 77.69 (+0.72), FNGN: 32.91 (+0.55), CPST: 0.92 (-0.02), AUQ: 3.78 (+0.27), AMRN: 0.95 (unch), ED: 62.03 (+0.03), ENV: 54.50 (+0.39), FXCM: 16.66 (+0.06), BCEI: 39.11 (+1.00), GXP: 26.38 (-0.05), EAC: 11.96 (-0.47), DXCM: 52.73 (-0.90), CSC: 61.76 (+0.09), AEL: 27.20 (+0.09), HNSN: 0.84 (+0.04), CFN: 57.57 (+0.01), ANAC: 31.00 (-0.46), DAR: 18.81 (+0.11), GST: 4.12 (+0.25), ARC: 9.59 (-0.29), FIVN: 4.97 (+0.03), ELON: 1.91 (-0.01), FSLR: 48.49 (+0.93), EZPW: 10.97 (-0.21), ALIM: 5.24 (+0.07), FWM: 2.30 (unch), BRS: 70.80 (-0.34), ECOM: 18.85 (-0.05), FTEK: 3.85 (-0.05), CVT: 28.15 (-0.10), AL: 36.97 (+0.03), BBRG: 13.15 (-0.02), BPZ: 1.00 (+0.06), ECPG: 44.62 (-0.61), HTGC: 15.56 (+0.04), AIRM: 44.22 (+0.23), BNFT: 26.65 (+0.61), ENOC: 15.21 (+0.42), HPTX: 21.19 (-0.40), AGO: 24.94 (+0.08), FICO: 71.44 (-0.37), FF: 12.42 (+0.24), FI: 20.63 (+0.61), EVC: 5.46 (+0.22), EBS: 24.22 (-0.10), ABCO: 46.38 (+0.16), DIOD: 26.34 (+0.57), DIS: 90.80 (+0.31), EGOV: 17.77 (+0.48), APEI: 36.62 (+0.77), DVA: 75.66 (-1.38), CLVS: 54.89 (-1.91), HCI: 43.04 (+1.24), BRKR: 18.11 (-0.19), HGR: 21.20 (-0.04)
Amarin to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November 6, 2014
ACCESSWIRE - Wed Nov 05, 3:56PM CST
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / November 5, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, November 6, 2014 at 4:30 PM Eastern Time.
AMRN: 0.95 (unch)
Amarin reports November 6
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:37PM CST
AMRN: 0.95 (unch)
Amarin to Report Third Quarter 2014 Results and Host Conference Call on November 6, 2014
Marketwired - Thu Oct 30, 6:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2014 financial results and provide an operational update on Thursday, November 6, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's third quarter 2014 financial results earlier that day.
AMRN: 0.95 (unch)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 14.68 (-0.92), BIIB: 305.43 (-12.55), AMRN: 0.95 (unch), UTHR: 125.43 (unch), NLNK: 30.54 (-0.46)
Amarin's Value With Or Without REDUCE-IT And A Final Word On Management
Outsized Analytics - Seeking Alpha - Wed Oct 22, 11:30PM CDT
For Amarin (NASDAQ: AMRN ) investors, the 4th quarter of 2014 may feel more like the 4th quarter of a game nearing its end; patiently waiting for your team to mount a historic comeback while closely monitoring its cash flow and hoping the clock does...
AMRN: 0.95 (unch)
Update: Amarin Announces Its Q3 2014 Cash Balance
Elephant Analytics - at Seeking Alpha - Mon Oct 20, 4:27AM CDT
AMRN: 0.95 (unch)
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
PR Newswire - Mon Sep 22, 7:40AM CDT
The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 751.48, up 0.10%, with the index gaining 6.95% in the previous three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free research on these five companies can be accessed at:
SGYP: 3.00 (-0.07), ENZN: 1.09 (unch), AMRN: 0.95 (unch), ALKS: 51.47 (-1.75), ARRY: 3.55 (-0.13)
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
MDVN: 106.90 (-0.31), OREX: 5.65 (-0.21), AVNR: 13.13 (-0.01), GILD: 102.06 (-2.14), AMRN: 0.95 (unch), NPSP: 29.00 (-0.78), CELG: 104.05 (-3.38)
Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study
Marketwire - Tue Sep 16, 12:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study. This multinational, prospective, randomized, double-blind, placebo-controlled study is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels.
AMRN: 0.95 (unch)
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
BIIB: 305.43 (-12.55), GILD: 102.06 (-2.14), AMRN: 0.95 (unch), AMGN: 157.68 (-3.17)
Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Fri Sep 12, 10:39AM CDT
Shares of Amarin (AMRN) plummeted Friday after the FDA denied Amarin's appeal to reinstate Special Protocol Assessment status on a phase III study of the company's prescription fish-oil pill Vascepa.
AMRN: 0.95 (unch)
Investors look to Lighten Up on Shares of Amarin, Shares Down 20.4% (AMRN)
Comtex SmarTrend(R) - Fri Sep 12, 10:08AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 20.4% to $1.44 on 2.4x average daily volume. Amarin has traded 6.8 million shares thus far today, vs. average volume of 2.9 million shares per day. The stock has underperformed the Dow (-20.4% to the Dow's -0.1%) and underperformed the S&P 500 (-20.4% to the S&P's -0.2%) during today's trading.
AMRN: 0.95 (unch)
Why Amarin Corporation plc Stock Cratered
George Budwell, The Motley Fool - Motley Fool - Fri Sep 12, 9:28AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin Corporation are down over 20%...
AMRN: 0.95 (unch), GSK: 45.74 (+0.08)
Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
at The Street - Fri Sep 12, 8:43AM CDT
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
AMRN: 0.95 (unch)
